story of the week
Cabozantinib Versus Everolimus in Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabozantinib Versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results From a Randomised, Open-Label, Phase 3 Trial
Lancet Oncol 2016 Jul 01;17(7)917-927, TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, HJ Hammers, F Donskov, BJ Roth, K Peltola, JL Lee, DY Heng, M Schmidinger, N Agarwal, CN Sternberg, DF McDermott, DT Aftab, C Hessel, C Scheffold, G Schwab, TE Hutson, S Pal, RJ Motzer,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.